Europe Asparaginase Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Application, and End-use Industry

The Europe asparaginase market is expected to grow from US$ 189.17 million in 2022 to US$ 451.68 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2022 to 2028.

Asparaginase is an enzyme, derived mostly from bacteria, and has wide applications in the pharmaceutical industry. Asparaginase is widely used to treat various conditions, such as acute myeloid leukemia, acute lymphoblastic leukemia, and non-Hodgkin's lymphoma. The prevalence of such diseases has increased significantly, creating a demand for effective treatment options. L-asparaginase is an important chemotherapeutic agent that is used in the treatment of lymphoma and leukemia. L-asparaginase breaks down asparagine from blood serum, leading to the death of tumor cells due to the lack of an essential factor for protein synthesis. However, healthy cells are not affected as they can produce asparagine using L-asparagine synthetase, which is available in adequate quantity. Moreover, it is also found to be effective in preventing metastasis from solid tumors.

In addition, various research studies are being conducted on the expansion of the application area of asparaginase in different industries, such as nanomedicine and biomedical engineering, which is contributing to the asparaginase market growth. Furthermore, increasing allergic reactions from E. coli, derived L-asparaginase has increased the use of E. chrysanthemi-derived L-Asparaginase. Many production methods for asparaginase are being developed, which include new bacterial strains, such as Pseudomonas fluorescens, E. coli, Serratia marcescens, Erwinia carotovora, Saccharomyces cerevisiae, and Proteus vulgaris. A few genres of fungi are also used, such as Penicillium, Aspergillus, and Fusarium. Thus, the increasing use o asparaginase in the treatment of diseases is boosting the Europe asparaginase market.

Market Overview

The Europe asparaginase market is segmented into Germany, France, Italy, Spain, the UK, and Rest of Europe. Further, Germany dominated the market in 2022. According to Robert Koch Institute, in 2018, ~12,200 people in Germany were diagnosed with leukemia, and ~4% of them were under 15 years of age. Further, approximately 18,470 people were diagnosed with non-Hodgkin lymphoma in the advanced age. Furthermore, growing pharmaceutical and increasing focus on research and development is expected to boost the market growth. Germany plays an important role in the global healthcare sector and leads in the production and distribution of high-quality pharmaceutical products worldwide. According to the Verband Forschender Arzneimittelhersteller (VFA), the country spends €6.2 billion on R&D, every year. In Germany, approximately half a million people are diagnosed with cancer every year. The German Cancer Research Center (DKFZ) with Helmholtz- ZentrumCentre Dresden-Rossendorf (HZDR) implemented a Cancer Research program that focuses on early diagnostics and treatment of cancer. Medac GMBH received EU-wide marketing authorization for Spectrila (Asparaginase), which is used for the treatment of acute lymphoblastic leukemia in infants, children, and adults. Thus, the growing prevalence of leukemia and increasing R&D activities for the treatment of the disease are expected to boost the market growth during the forecast period.

Europe Asparaginase Market Segmentation

The Europe asparaginase market is segmented based on type, application, end-use industry, and country.

• Based on type, the Europe asparaginase market is segmented into escherichia coli, erwinia chrysanthemi, pegylated, and others. The escherichia coli segment held the largest market share in 2022.
• Based on application, the Europe asparaginase market is segmented into therapeutic, food processing, and others. The therapeutic segment held the largest market share in 2022. The therapeutic segment is further classified into acute lymphoblastic leukemia, lymphoblastic lymphoma, and others.
• Based on end-use industry, the Europe asparaginase market is bifurcated into healthcare and food manufacturing. The healthcare segment held the larger market share in 2022.
• Based on country, the Europe asparaginase market has been categorized into the UK, Germany, France, Italy, Spain, and rest of Europe. Our regional analysis states that Germany dominated the market in 2022. Biovendor, LLC; Changzhou Qianhong Biopharma Co Ltd; Creative Enzymes; Jazz Pharmaceuticals, Inc.; medac GMBH; Porton Biopharma; Servier Pharmaceuticals LLC; Taj Pharmaceuticals Limited; and United Biotech (P) Limited are the leading companies operating in the Europe asparaginase market.